A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Название протокола
Клинические исследование Colorectal Cancer: favezelimab/pembrolizumab, regorafenib, TAS-102 - Реестр клинических исследований
